AstraZeneca and Merck & Co., Inc. are jointly developing ... In 30-50% of patients, tumours develop on the nerve sheaths and may cause debilitating symptoms. There are no approved treatments for ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

LONDON, Nov 6 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.